IASO Therapeutics
IASO Therapeutics is commercializing a cancer treatment by targeting tumor associated carbohydrate and glyco-conjugate antigens (TACAs). The underlying technology is the development of novel protein carriers to powerfully boost antibody responses against weakly immunogenic antigens, such as those found on cancer cells.